An interview with Giuseppe Argenziano: an insight into the field of dermoscopy [0.03%]
Giuseppe Argenziano教授访谈：带你走进皮肤镜世界
Giuseppe Argenziano
Giuseppe Argenziano
Giuseppe Argenziano speaks to Sebastian Dennis-Beron, Commissioning Editor: Giuseppe Argenziano is Full Professor and Head of the Dermatology Unit at the University of Campania, Naples, Italy. His main research field is dermato-oncology. He...
Justine V Cohen,Ryan J Sullivan
Justine V Cohen
Welcome to the fourth volume of Melanoma Management and a look back at 2016 [0.03%]
欢迎来到黑色素瘤管理杂志第四卷及回望2016年
Sebastian Dennis-Beron
Sebastian Dennis-Beron
Robert O Dillman,Gabriel I Nistor,Andrew N Cornforth
Robert O Dillman
Administering dendritic cells (DC) loaded with tumor-associated antigens (TAA) ex vivo is a promising strategy for therapeutic vaccines in advanced melanoma. To date the induction of immune responses to specific TAA has been more impressive...
Talimogene laherparepvec: overview, combination therapy and current practices [0.03%]
talimogene laherparepvec：概述、联合疗法和当前实践
Cristina O&#x;Donoghue,Matthew P Doepker,Jonathan S Zager
Cristina O&#x;Donoghue
Talimogene laherparepvec (T-VEC, Imlygic®, Amgen, CA, USA) is an oncolytic herpes simplex type 1 virus used as intralesional therapy for unresectable metastatic melanoma in a cutaneous, subcutaneous or nodal location. Talimogene laherparep...
Daniel Y Wang,Douglas B Johnson
Daniel Y Wang
Advances in immune therapy have changed the landscape of advanced melanoma treatment. Intralesional therapy is an important type of immune therapy due to its efficacy and safety, especially in the setting of locoregional metastases. These t...
Adam I Riker,Erika Bisgaard
Adam I Riker
Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma [0.03%]
疫苗疗法联合Dasatinib治疗IIIB-IV期黑色素瘤患者
Ahmad A Tarhini,Hussein Tawbi,Walter J Storkus
Ahmad A Tarhini
The use of dendritic cell vaccinations in melanoma: where are we now? [0.03%]
黑色素瘤中的树突状细胞疫苗的应用：目前进展如何？
Altuna Halilovic,Kalijn F Bol
Altuna Halilovic
Melanoma vaccines and viral-based immunotherapies: a special focus issue from Melanoma Management [0.03%]
黑色素瘤疫苗和基于病毒的免疫疗法：来自黑色素瘤管理杂志的重点专题报道
Robert O Dillman,Sebastian Dennis-Beron
Robert O Dillman